Share-based Payment Arrangement, Expense of Solid Biosciences Inc. from 31 Dec 2016 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Solid Biosciences Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2016 to 30 Sep 2025.
  • Solid Biosciences Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3,928,000, a 31% increase year-over-year.
  • Solid Biosciences Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $14,235,000, a 65% increase year-over-year.
  • Solid Biosciences Inc. annual Share-based Payment Arrangement, Expense for 2024 was $10,519,000, a 38% increase from 2023.
  • Solid Biosciences Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7,625,000, a 1.2% increase from 2022.
  • Solid Biosciences Inc. annual Share-based Payment Arrangement, Expense for 2022 was $7,537,000, a 44% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Solid Biosciences Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $14,235,000 $3,928,000 +$933,000 +31% 01 Jul 2025 30 Sep 2025 10-Q 03 Nov 2025 2025 Q3
Q2 2025 $13,302,000 $3,145,000 +$1,053,000 +50% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $12,249,000 $3,341,000 +$1,730,000 +107% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $10,519,000 $3,821,000 +$1,883,000 +97% 01 Oct 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
Q3 2024 $8,636,000 $2,995,000 +$1,370,000 +84% 01 Jul 2024 30 Sep 2024 10-Q 03 Nov 2025 2025 Q3
Q2 2024 $7,266,000 $2,092,000 +$148,000 +7.6% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $7,118,000 $1,611,000 -$507,000 -24% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $7,625,000 $1,938,000 +$351,000 +22% 01 Oct 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
Q3 2023 $7,274,000 $1,625,000 +$101,000 +6.6% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $7,173,000 $1,944,000 +$130,000 +7.2% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $7,043,000 $2,118,000 -$494,000 -19% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $7,537,000 $1,587,000 -$1,828,000 -54% 01 Oct 2022 31 Dec 2022 10-K 13 Mar 2024 2023 FY
Q3 2022 $9,365,000 $1,524,000 -$1,892,000 -55% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $11,257,000 $1,814,000 -$1,821,000 -50% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $13,078,000 $2,612,000 -$295,000 -10% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $13,373,000 $3,415,000 +$897,000 +36% 01 Oct 2021 31 Dec 2021 10-K 13 Mar 2024 2023 FY
Q3 2021 $12,476,000 $3,416,000 +$652,000 +24% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $11,824,000 $3,635,000 +$392,000 +12% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $11,432,000 $2,907,000 -$197,000 -6.3% 01 Jan 2021 31 Mar 2021 10-Q 27 Apr 2022 2022 Q1
Q4 2020 $11,629,000 $2,518,000 -$886,000 -26% 01 Oct 2020 31 Dec 2020 10-K 23 Mar 2023 2022 FY
Q3 2020 $12,515,000 $2,764,000 -$628,000 -19% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $13,143,000 $3,243,000 -$668,000 -17% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2
Q1 2020 $13,811,000 $3,104,000 -$396,000 -11% 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021 2021 Q1
Q4 2019 $14,207,000 $3,404,000 +$1,374,000 +68% 01 Oct 2019 31 Dec 2019 10-K 14 Mar 2022 2021 FY
Q3 2019 $12,833,000 $3,392,000 +$1,595,000 +89% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $11,238,000 $3,911,000 +$2,602,000 +199% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $8,636,000 $3,500,000 +$2,681,000 +327% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $5,955,000 $2,030,000 +$1,207,000 +147% 01 Oct 2018 31 Dec 2018 10-K 15 Mar 2021 2020 FY
Q3 2018 $4,748,000 $1,797,000 +$1,007,000 +127% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $3,741,000 $1,309,000 +$822,000 +169% 01 Apr 2018 30 Jun 2018 10-Q 14 Aug 2019 2019 Q2
Q1 2018 $2,919,000 $819,000 -$2,411,000 -75% 01 Jan 2018 31 Mar 2018 10-Q 13 May 2019 2019 Q1
Q4 2017 $5,330,000 $823,000 01 Oct 2017 31 Dec 2017 10-K 12 Mar 2020 2019 FY
Q3 2017 $790,000 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018 2018 Q3
Q2 2017 $487,000 30 Mar 2017 30 Jun 2017 10-Q 10 Aug 2018 2018 Q2
Q1 2017 $3,230,000 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1

Solid Biosciences Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $10,519,000 +$2,894,000 +38% 01 Jan 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
2023 $7,625,000 +$88,000 +1.2% 01 Jan 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
2022 $7,537,000 -$5,836,000 -44% 01 Jan 2022 31 Dec 2022 10-K 13 Mar 2024 2023 FY
2021 $13,373,000 +$1,744,000 +15% 01 Jan 2021 31 Dec 2021 10-K 13 Mar 2024 2023 FY
2020 $11,629,000 -$2,578,000 -18% 01 Jan 2020 31 Dec 2020 10-K 23 Mar 2023 2022 FY
2019 $14,207,000 +$8,252,000 +139% 01 Jan 2019 31 Dec 2019 10-K 14 Mar 2022 2021 FY
2018 $5,955,000 +$625,000 +12% 01 Jan 2018 31 Dec 2018 10-K 15 Mar 2021 2020 FY
2017 $5,330,000 +$3,860,000 +263% 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2020 2019 FY
2016 $1,470,000 01 Jan 2016 31 Dec 2016 10-K 13 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.